<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc050414.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 13 April, 2005  By /s/Ronald Lea Erratt Company Secretary


ASX & MEDIA RELEASE
14 APRIL, 2005

NOVOGEN US SUBSIDIARY COMPANY GLYCOTEX INC SETTLES A PRIVATE CAPITAL
RAISING

[SYDNEY AUSTRALIA].   Novogen Limited [NASDAQ: NVGN] has announced
that its US subsidiary company, Glycotex Inc., has placed 10% of its
stock with a US professional investor for US$4million.

Novogen retains 84.3% of the company.

Glycotex, Inc., holds a licence from Novogen Limited for the
Company's 1, 3, 6, beta-glucan technology which is being developed
for the promotion of tissue repair across a range of applications.

The first of those applications is trophic ulcers, which includes
ulcers due to venous stasis, arterial disease, diabetes and bed-sores.

Glycotex is conducting a clinical trial in Australia in this area
using the proprietary glucan compound, "Glucoprime".

The double-blind, placebo-controlled Phase II trial is being conducted
in patients with chronic venous stasis ulcers of the legs.

Venous stasis ulcers are the most common form of skin ulcer in
the community, and the problem is a major community health issue.

The results of the Phase II trial are expected to be available
mid-year.

The equity raised will be used to further advance the next stage
of clinical development of Glucoprime, to extend the technology
into other areas of tissue repair, and for the corporate
development of Glycotex Inc.

Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical trials.  After the results of these
trials are submitted in a new drug application to the FDA,
the FDA must approve the drug as safe and effective before
marketing can take place.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
